Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. (2014)

First Author: Seymour JF
Attributed to:  MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjh.12723

PubMed Identifier: 24467613

Publication URI: http://europepmc.org/abstract/MED/24467613

Type: Journal Article/Review

Volume: 165

Parent Publication: British journal of haematology

Issue: 1

ISSN: 0007-1048